Therapeutic Goods Information (Exemptions from Annual Charges) Specification 2016

The instrument operates around a small set of concepts defined in the text and Schedule 1. The key defined terms are Act, Annual Charges Exemption Scheme, ARTG, Regulations and Sponsor (s 3). These definitions are minimal but decisive for reading the Specification. The term Annual Charges Exemption Scheme points to a scheme set out in Subdivision 2 of Division 1 of Part 7 of the Regulations; the Specification does not reproduce that scheme, but it attaches disclosure to positions within that scheme.

Subsectional references in the instrument show the legal mechanism: subsection 61(5D) of the Act authorises the Minister or delegate to make a specification of kinds of information for disclosure under subsection 61(5C). The Specification therefore performs a defining function for the statutory disclosure power in s 61(5C). Schedule 1 then categorises the disclosure types according to two factual states: (1) where a sponsor was exempt from the annual charge in a particular financial year, and (2) where a sponsor declared low-value turnover, did not pay the charge, but was subsequently notified by the Secretary that the exemption did not apply. For each state the Schedule specifies four discrete data elements: sponsor name, ARTG number, product name as on the ARTG entry, and a statement summarising the exemption status for the particular financial year (Schedule 1 items (a)-(d) for each group).

The Specification relies on cross-referenced provisions in the Regulations. The Schedule explicitly links disclosure in the second group to declarations under regulation 43AAC or 43AAD and to notices under subregulation 43AAG(2) or (4). Those cross-references provide the trigger conditions that make a given ARTG entry and sponsor fall into the second disclosure category.

The instrument thereby creates a pair of disclosure categories which are symmetric in form but asymmetric in implication. Both categories disclose identifying information tied to ARTG entries and to a financial-year-specific status. The substance of disclosures differs only in whether the declared exemption was accepted or was subsequently found not to apply, as recorded by a Secretary's notice. The Specification does not itself set thresholds or tests for exemption; those are governed by the Regulations. The Specification does not mandate publication frequency, format, or the Secretary's process for publication beyond stating what may be released under s 61(5C).

Finally, the instrument contains a s 4 direction that the listed kinds of information are "specified" under subsection 61(5D) for the purposes of subsection 61(5C) of the Act. The Schedule also contains an internal Note stating that the specified kinds "may be released by the Secretary to the public under subsection 61(5C) of the Act." That language frames the Specification as enabling a discretionary publication power rather than imposing an obligation to publish.

The Specification directly affects sponsors of therapeutic goods whose goods are registered, listed or included in the Australian Register of Therapeutic Goods, the ARTG. The Schedule identifies sponsors by name when the sponsor was exempt from paying an annual charge in a particular financial year, and when a sponsor declared low turnover but the Secretary later issued a notice that the sponsor was not exempt (Schedule 1, the two disclosure groups, items (a)-(d)). Consequently, sponsors who use the Annual Charges Exemption Scheme, or who make declarations under regulations 43AAC or 43AAD, are the primary subjects of the Specification.

The instrument also indirectly affects the Secretary and the Department responsible for administering the ARTG and the Annual Charges Exemption Scheme. The Specification sets out the kinds of information the Secretary may release to the public under s 61(5C). That creates an administrative task for the Secretary to identify, extract and publish the specified data elements from ARTG records and from the Secretary's file of exemption notices. The instrument therefore assigns an informational role to the Secretary when exercising the disclosure power.

Third parties are affected in informational and economic ways. Public disclosure of sponsor names, ARTG numbers and product names, together with the fact of an exemption or of a notice that an exemption did not apply, provides other market participants, consumers, journalists and compliance officers with data they did not necessarily have before. The Specification thus affects stakeholders who monitor market entry, compliance with regulatory charges, or reputational signals in the therapeutic goods market. The instrument also affects recipients of therapeutic goods information, because it clarifies what the Secretary may publish about exemptions and reversed exemptions.

Regulatory stakeholders beyond sponsors and the Secretary are implicated by the cross-references to the Regulations. Entities engaged in preparing declarations under regulation 43AAC or 43AAD,such as accountants and in-house compliance teams,face the prospect that those declarations and the subsequent administrative outcomes could become public in the ways specified. The Specification therefore shifts the informational environment for several actor groups: sponsors who make declarations; the Secretary who may publish; and any observers who rely on public ARTG-related disclosures to assess market behaviour or compliance.

The Specification does not itself alter who is liable to pay charges, nor does it change the criteria for exemption. Those substantive liabilities and criteria remain in the Regulations. The Specification's effect is confined to specifying which data points tied to exemption outcomes may be published.

The Specification does not create substantive duties to pay or to claim exemptions; those duties are determined by the Act and the Regulations. The Specification does, however, define what information may be disclosed by the Secretary under the disclosure power in subsection 61(5C) of the Act. Section 4 limits the Secretary's potential public release to the kinds of therapeutic goods information set out in Schedule 1. Consequently, a practical duty for the Secretary arises to restrict any public disclosure under s 61(5C) to the specified categories: sponsor name, ARTG number, product name as recorded in the ARTG, and a statement of exemption status for a particular financial year, for each of the two disclosure categories in Schedule 1.

Rights that flow from the Specification are primarily informational rights exercisable by the public and third parties under the Act's disclosure mechanism. The Schedule contains an explicit note that the specified kinds of information "may be released by the Secretary to the public under subsection 61(5C) of the Act." This phrasing indicates that the power to release is discretionary rather than mandatory; the Secretary may but is not required to publish those data. The Specification therefore narrows the content of any such disclosure but does not oblige the Secretary to disclose in all cases.

Sponsors retain procedural rights and obligations under the Regulations, to the extent those are relevant. The Schedule ties one disclosure category to declarations made under regulation 43AAC or 43AAD and to notices under subregulation 43AAG(2) or (4). Although the Specification does not set the procedural mechanics for those declarations and notices, the linkage means that a sponsor's statutory interaction with those regulatory procedures will affect whether the Secretary may, in the exercise of the s 61(5C) power, publish the specified information.

The Specification contains no express confidentiality carve-outs, exemptions for commercially sensitive information, or limitations based on privacy law. It also does not prescribe the timing, manner or format of release. Those procedural and substantive constraints would therefore derive from the Act more broadly, the Regulations, privacy and administrative law, or administrative practice. The Specification confines the Secretary's permissible public disclosures to the specified categories; it does not create an independent right of veto for sponsors over such disclosures.

Finally, the Specification imposes an indirect obligation on sponsors to be mindful of the public nature of certain outcomes. If a sponsor is exempted for a financial year under the Annual Charges Exemption Scheme, or if a sponsor makes a low-turnover declaration but is later notified that the exemption did not apply, the sponsor can be named publicly in the categories specified. That public naming is not framed as a penalty by the instrument; it is a permissible disclosure that follows from the interaction of the Act, the Regulations and this Specification.

This Specification does not itself create criminal offences, civil penalties, or an enforcement regime. Its legal effect is to specify the kinds of information that the Secretary may publish under s 61(5C) of the Therapeutic Goods Act. The substantive enforcement mechanisms for annual charges, declarations of low turnover, and the issuing of notices that an exemption does not apply are governed by the Regulations and the Act; the Specification is a disclosure-focused instrument that complements those regimes by defining publishable data elements.

Because the Specification ties disclosure in the second category to subregulation 43AAG(2) or (4), it presupposes that administrative processes exist in the Regulations to determine whether an exemption applies and to notify sponsors if an exemption is found not to apply. The Schedule states that disclosure may follow when the Secretary has given a notice under those subregulation provisions. Any enforcement action, such as recovery of unpaid charges, imposition of penalties for false declarations, or other regulatory sanctions, would flow from the Regulations and the Act, not from this Specification.

The Specification may, however, influence enforcement indirectly by enabling public transparency about exemption outcomes. Where the Secretary elects to publish the specified information, disclosure may amplify oversight by third parties, including market competitors, journalists, consumer groups, and auditors. That amplified oversight could lead to third-party complaints, media scrutiny, or triggers for regulatory follow-up under existing enforcement provisions of the Act and the Regulations. Those are indirect enforcement effects arising from disclosure, not direct penalties imposed by the Specification.

The instrument does not create private causes of action for disclosure, nor does it provide any statutory compensation mechanism for sponsors whose information is published. It is also silent about remedies or review processes specific to disclosure decisions under s 61(5C). Any challenge to a disclosure decision, or to the Secretary's compliance with the limits set by this Specification, would have to be grounded in the Act, the Regulations, or in general administrative law. The Specification therefore creates boundaries for lawful disclosure but does not itself set out the legal consequences of disclosure decisions.

The Specification explicitly cross-references the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990. It is made under subsection 61(5D) of the Act and exists for the purposes of subsection 61(5C) (instrument heading; s 4). The Annual Charges Exemption Scheme referred to in s 3 is located in Subdivision 2 of Division 1 of Part 7 of the Regulations; the Specification does not alter those regulatory provisions but specifies which information relating to that scheme may be disclosed.

The Schedule links disclosure triggers to regulation 43AAC and regulation 43AAD, which are the provisions under which sponsors may declare low-value turnover, and to subregulation 43AAG(2) and (4), under which the Secretary can give a notice that an exemption did not apply. The Specification therefore operates as an informational adjunct to the regulatory procedures in those clauses. It relies on the determinations, notices and records created under the Regulations to populate the categories of information it authorises for disclosure.

Beyond the Act and the Regulations, the Specification does not mention privacy, secrecy or freedom of information statutes. Its silence does not mean those laws are inapplicable. In practice, publication decisions would need to be assessed against relevant privacy or secrecy obligations under Commonwealth law; however, the Specification itself constrains the Secretary to particular kinds of information that may be disclosed under s 61(5C). Any conflict between this Specification and other Commonwealth disclosure or privacy statutes would have to be resolved by reference to the hierarchy of laws, interpretive rules, and specific statutory provisions outside this instrument.

The instrument also notes the Federal Register of Legislative Instruments as the repository for legislative instruments and compilations (Schedule Note). That indicates the Specification will be publicly accessible in the FRLI system, consistent with statutory registration obligations under the Legislative Instruments Act 2003. The Specification therefore interacts procedurally with the legislative instruments regime for registration and public notice.

In short, the Specification is a narrowly focused, subordinate instrument that modifies the information architecture around existing charging and exemption rules in the Regulations. It does not alter substantive liability rules or create new regulatory offences; its effect is to delineate the kinds of ARTG-linked information that the Secretary may release in relation to the Annual Charges Exemption Scheme and related declaration and notice processes.

The instrument declares its own name in s 1, and its commencement date is 1 July 2016 (s 2). It was made by a delegate of the Minister for Health and dated 4 May 2016 (instrument header and signature). The Specification contains no internal amendments, disallowance clauses or sunset provisions, and there are no recorded amendments within the body of the instrument itself. The text supplied does not show any subsequent variations, revocations, or replacement instruments.

The Schedule includes a Note that legislative instruments and compilations are registered on the Federal Register of Legislative Instruments, and it gives a web address for the FRLI. That procedural note suggests that the canonical instrument and any subsequent amendments should be discoverable through FRLI, but the instrument as provided does not show whether any amendments have subsequently been made.

Because the Specification is made under subsection 61(5D) of the Act, any amendment or revocation would presumably follow the same delegated-making power and the usual legislative instruments processes, including registration on FRLI and any applicable parliamentary oversight mechanisms. The Specification itself does not state whether it is a disallowable instrument or specify the parliamentary pathways for disallowance; those matters are determined by the Act and the Legislative Instruments Act 2003.

Practitioners wanting to confirm the current text should consult the FRLI entry for the Specification, and should check whether the Regulations (not reproduced here) have been amended in ways that change the triggers or content of the disclosure categories. Since the Specification ties disclosure to particular regulatory provisions (regs 43AAC, 43AAD and 43AAG), amendments to those regulations could change the operational meaning of Schedule 1 without any textual change in the Specification.

The instrument does not include a retrospective clause. Its commencement on 1 July 2016 suggests it was intended to take effect from the start of an Australian financial year, which aligns with the Specification's focus on financial-year-specific exemption status. The Specification therefore appears designed to operate on an annual-accounting cycle, but it contains no express transitional arrangements.

The text provided contains no litigation history, and it does not cite any cases. The Specification is an administrative instrument that defines what information may be disclosed under the Act; it does not set out dispute resolution or judicial review steps within its own text. The absence of litigation references in the instrument does not mean litigation is impossible, but the Specification itself provides no record of judicial consideration.

Potential litigation or challenges arising from the Specification would likely concern administrative decisions by the Secretary to publish or not publish the specified information, the interpretation of the cross-referenced regulatory provisions (for example, whether a notice under subregulation 43AAG(2) or (4) was properly given), or conflicts with privacy and other statutory protections. Any judicial review or merits review claims would have to be grounded in the Act, the Regulations, or in general administrative law principles. The Specification, by specifying permissible categories, could be relied upon in a judicial review challenge as defining the outer limits of lawful disclosure under s 61(5C).

In the absence of specific case law cited in the instrument, counsel and compliance teams should be alert to two litigation-conducive facts embedded in the Specification. First, the instrument discloses identifiable sponsor details tied to particular financial years; that factual specificity creates concrete standing arguments for an affected sponsor or third party. Second, the Specification does not itself provide procedural detail about how disclosure decisions are to be taken, leaving space for procedural fairness or administrative-law-based challenges if a sponsor alleges the Secretary failed to follow lawful process in deciding to publish.

Practitioners preparing for potential litigation should therefore track Secretary decisions to publish under s 61(5C), record the administrative file around declarations and notices under regs 43AAC, 43AAD and 43AAG, and consider privacy and other legal constraints in anticipating grounds for or against litigation. The Specification itself does not furnish precedent or doctrinal guidance; it simply defines the data fields that could appear in any public disclosures subject to the Act's broader legal framework.

The Specification is narrow in scope, and several practical pitfalls arise from that narrowness.

1. Disclosure is permitted, not mandatory. The Schedule states the kinds of information "may be released by the Secretary to the public under subsection 61(5C) of the Act." This means a sponsor cannot assume non-disclosure simply because the Specification lists the data categories; the Secretary retains discretion to publish. For sponsors, the risk is unpredictability of publication rather than an automatic sanction.

2. Identification is financial-year specific. The Schedule ties each disclosure to "a particular financial year" and to the sponsor's financial-year-specific exemption status. Sponsors that rely on low-turnover declarations should therefore treat their records on a per-financial-year basis, since disclosure can be tied to that discrete period.

3. Symmetry of published elements. The Specification publishes identical data fields whether the sponsor was exempt or was found not to be exempt. That symmetry means that the mere presence of a sponsor's name on a published list does not distinguish whether the outcome was an accepted exemption or a reversed claim. The Schedule does include a descriptive item for each group stating whether the sponsor "was exempt" or "was not exempt", but the practical result is that both positive and negative administrative outcomes produce similar public visibility.

4. Linkage to regulation-based triggers. For the second disclosure category, publication is linked to declarations under regs 43AAC/43AAD and to a Secretary notice under subreg 43AAG(2) or (4). Sponsors should not treat the Specification as an independent source of definitions for these concepts. Any change to those regulations, or any dispute about whether a notice under 43AAG was validly given, will affect whether the Secretary can lawfully publish.

5. No express privacy or commercial-sensitivity shield. The Specification names sponsor names, ARTG numbers and product names without carving out commercially sensitive data or setting publication limits. If sponsors expect confidentiality for certain records, that expectation must be evaluated against other statutory privacy protections and administrative law; the Specification itself does not provide such shields.

6. Administrative cost and timing uncertainties. The Specification does not set timing or format for publication. This creates uncertainty for sponsors about when a disclosure may appear publicly, and for third parties about how up to date any published information will be. For a sponsor concerned about reputational impact, the absence of timing rules is a significant operational gap.

7. Interplay with unpaid charges. The second disclosure category presumes a sponsor declared low-value turnover and did not pay the annual charge, but later received a notice that the exemption did not apply. Publication of such an outcome could be read publicly as a signal of non-payment. The Specification does not address whether the Secretary will coordinate disclosure with recovery actions under the Regulations, but the public association between the sponsor and a non-exemption notice could carry reputational costs.

8. Reliance on ARTG entry text. The Specification requires publication of "the name of the therapeutic goods as it appeared in the relevant ARTG entry." That means the historical text of ARTG entries matters. Inaccuracies or later changes to an ARTG entry may complicate what is published about a prior financial year. Sponsors should therefore keep contemporaneous records of ARTG entries and the exact text as it appeared at the time of the exemption decision.

9. Registration and discoverability. The instrument notes that legislative instruments are registered on FRLI. However, the Specification does not expressly state whether the Secretary's eventual public disclosures will also be published via FRLI, the Department website, or the ARTG public interface. Sponsors and third parties will need to monitor the Department's disclosure practices to locate published information.

These points are practical rather than legal criticisms. They identify how a narrow specification of data fields, combined with discretionary publication and absent procedural detail, can create uncertainty and operational exposure for sponsors and administrative obligations for the Secretary.

Sponsors and advisers should adopt a small set of focused, verifiable steps to manage the disclosure risk created by the Specification.

1. Treat declarations as public-facing events. When making a declaration under regulation 43AAC or 43AAD that a product's turnover was of low value for a financial year, document the factual basis and supporting records. The Specification links publication to such declarations, so contemporaneous, auditable records reduce the risk of adverse administrative findings that could trigger publication (see Schedule 1, second disclosure category).

2. Preserve ARTG entry snapshots. Because the Specification requires publication of "the name of the therapeutic goods as it appeared in the relevant ARTG entry," keep an archived copy of the ARTG entry as it stood at the relevant date. This will assist in any administrative correspondence about what text is referenced in a publication.

3. Monitor notices under subregulation 43AAG. The second disclosure category is triggered by a Secretary notice under subregulation 43AAG(2) or (4) stating that a sponsor was not exempt. Sponsors should actively monitor correspondence from the Secretary concerning annual charge eligibility, respond promptly to notices, and maintain a clear file trail of communications.

4. Reconcile annual charge payments and records. Ensure that accounting and compliance systems reconcile declarations of low turnover, invoices for annual charges, and payment records for each financial year. The Specification connects publication to financial-year-specific outcomes; good bookkeeping reduces factual disputes.

5. Prepare a communications plan. Because publication may be discretionary and may name sponsor and product, prepare an external communications plan that explains the administrative posture if the Secretary elects to publish. That plan should include factual documentation, a legal view of the declaration and notice, and a public statement strategy.

6. Consider pre-emptive engagement. Where a sponsor believes a declaration is likely to be questioned, consider pre-emptive engagement with the Secretary to clarify records or to remedy apparent reporting errors before a notice under 43AAG is issued. Early engagement may reduce the chance that corrective notices lead to public disclosure.

7. Check the FRLI and Department publication channels. The Specification notes FRLI as the registration repository for legislative instruments. For actual Secretary disclosures under s 61(5C), sponsors should monitor the Department of Health's public interfaces and the ARTG public search for any published lists or announcements. If no centralised publication practice is apparent, request administrative clarification from the Secretary's office regarding usual publication channels.

8. Legal review if a notice is issued. If a notice under 43AAG(2) or (4) is given, consider a prompt legal review of the notice, supporting evidence and available remedies under the Act and Regulations. Because the Specification makes such notices potential targets for public disclosure, ensuring the legal defensibility of the Secretary's determination is important.

9. Keep privacy considerations under review. Although the Specification itself does not provide exemptions for privacy or commercially sensitive material, sponsors should review confidentiality obligations and, where appropriate, consider whether specific disclosure would engage privacy legislation or other legal limits. Seek legal advice before assuming such protections apply.

10. Document all communications and calculations. Administrative decisions about exemptions and about the existence of low-turnover declarations will depend on documentary evidence. Retain calculation workpapers, invoices, sales data, and correspondence for each financial year so that any administrative or judicial review has a robust evidentiary foundation.

These steps are procedural and evidential responses to the Specification's disclosure mechanism. They do not alter substantive rights under the Act and the Regulations, but they provide practical controls to reduce the risk of adverse public disclosure and to enable timely responses if the Secretary exercises the s 61(5C) power.